42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
2 citations
,
June 2017 in “Journal of Evidence Based Medicine and Healthcare” Skin and mucous symptoms are key for diagnosing autoimmune connective tissue diseases.
April 2020 in “Rheumatology” Many patients with Giant Cell Arteritis did not follow their steroid treatment plans properly.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” A woman with rheumatoid arthritis had a unique type of scarring hair loss not caused by infection, requiring early treatment to avoid permanent hair loss.
3 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” The woman's facial symptoms are best explained by primary Sjögren’s Syndrome.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
2 citations
,
December 2023 in “Mediterranean Journal of Rheumatology” Late onset SLE has different symptoms and antibody profiles compared to young onset SLE.
1 citations
,
September 2023 in “Rheumatology advances in practice” A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
September 2021 in “Pediatrics in review” A baby with KID syndrome died from infections and organ failure at 18 months old.
January 2002 in “대한피부과학회지” Most patients with dermatomyositis had skin rash and were treated with prednisolone and hydroxychloroquine.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
June 2026 in “Frontiers in Immunology” JAK inhibitors effectively treat inflammatory skin diseases by targeting specific cytokine signals.
2 citations
,
January 2021 in “Case reports in endocrinology” The girl's condition improved with treatment, showing no new autoimmune diseases and hair regrowth.
13 citations
,
May 2014 in “PubMed” Most children with childhood-onset lupus in Baghdad responded well to treatment, but some developed chronic kidney disease or died.
Careful diagnosis and management of MCTD are crucial due to potential severe complications.
January 2025 in “Annals of Clinical Reviews & Case Reports” Early diagnosis and a multidisciplinary approach are key to managing Sjogren's Disease symptoms.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” Plaquenil can cause a severe skin reaction called AGEP, requiring prompt diagnosis and treatment.
1 citations
,
March 2023 in “International journal of rheumatic diseases” Relatives of lupus patients show signs of immune system activity but not full-blown lupus.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
38 citations
,
January 2017 in “Mediators of Inflammation” Platelet-released growth factors can reduce inflammation in joint disease.
13 citations
,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
June 2025 in “Medical alphabet” JAK inhibitors may help treat alopecia areata in children, but their safety needs careful evaluation.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
December 2022 in “Biological and Clinical Sciences Research Journal” Early treatment of mixed connective tissue disease is crucial to prevent severe autoimmune conditions.